TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31116468

Group type: EXPERIMENTAL
Intervention: Various treatments/interventions in physiological research studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less biased approaches for estimating the proportion of responders
Number of subjects: 0
Study: 26001567

Group type: COMPARATOR
Intervention: Rivastigmine 0mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine 1.5mg twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3mg twice a day
Number of subjects: 0
Study: 23860506

Group type: EXPERIMENTAL
Intervention: Young Athletes (YA) intervention group
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 233
Study: 22097126

Group type: EXPERIMENTAL
Intervention: Pizhen manipulation
Number of subjects: 83

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 83
Study: 19781326

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 16756730

Group type: EXPERIMENTAL
Intervention: Velocity port
Number of subjects: 40

Group type: COMPARATOR
Intervention: classic titanium port
Number of subjects: 40
Study: 15315849

Group type: EXPERIMENTAL
Intervention: Duplex vaccine
Number of subjects: 22365

Group type: EXPERIMENTAL
Intervention: diTeBooster vaccine
Number of subjects: 22365

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 22365
Study: 11535983

Group type: EXPERIMENTAL
Intervention: PTX plus carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) + PTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin (CP) alone
Number of subjects: 0
Study: 9311648

Group type: EXPERIMENTAL
Intervention: Artesunate suppositories (200 mg/capsule) given rectally at 0, 4, 8, 12, 24, 36, 48, and 60 hr (total = 1,600 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Artesunate suppositories (200 mg/capsule) given rectally at 0, 12, 24, 36, 48, and 60 hr (total = 1,200 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Number of subjects: 63
Study: 8110401

Group type: EXPERIMENTAL
Intervention: Rice-based solution without electrolytes (Group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Rice-based solution with electrolytes (Group B)
Number of subjects: 22
Study: 2437278

Group type: EXPERIMENTAL
Intervention: High-dose gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d
Number of subjects: 136

Group type: COMPARATOR
Intervention: Aspirin alone at the same dosage (30 mg/kg/d)
Number of subjects: 136
Study: 31380660

Group type: EXPERIMENTAL
Intervention: Reminiscing and Emotion Training (RET)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Community Standard (CS)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Nonmaltreating comparison condition
Number of subjects: 248
Study: 29685870

Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based stress intervention group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 150
Study: 26669827

Group type: EXPERIMENTAL
Intervention: Target Inhalation Mode (TIM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tidal Breathing Mode (TBM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Single dose of 77 mg of A1-PI
Number of subjects: 21
Study: 24671858

Group type: EXPERIMENTAL
Intervention: MMD (midazolam-meperidine-dexmedetomidine)
Number of subjects: 110

Group type: COMPARATOR
Intervention: midazolam-meperidine
Number of subjects: 110
Study: 22644357

Group type: EXPERIMENTAL
Intervention: Epineural buprenorphine 0.15 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine 0.15 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 150
Study: 20412135

Group type: EXPERIMENTAL
Intervention: AIC-treated (n=17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo-treated (n=15)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 18616367

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+) until surgical closure of the soft palate at the age of +/- 52 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: No intervention (IO-)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+)
Number of subjects: 54
Study: 15165913

Group type: EXPERIMENTAL
Intervention: Carbofilm-coated stent
Number of subjects: 420

Group type: COMPARATOR
Intervention: Stainless steel stent
Number of subjects: 420
Study: 11481927

Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.243% sodium fluoride in a silica base and dicalcium phosphate dihydrate)
Number of subjects: 2432

Group type: COMPARATOR
Intervention: Positive Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 2432

Group type: EXPERIMENTAL
Intervention: Test Dentifrice
Number of subjects: 2432

Group type: COMPARATOR
Intervention: Positive Control Dentifrice
Number of subjects: 2432
Study: 9513627

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard Counseling
Number of subjects: 180
Study: 8063978

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy (CB)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy (PI)
Number of subjects: 117
Study: 2494098

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 791333

Group type: EXPERIMENTAL
Intervention: Labetalol 1.0‐2.0 mg/kg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propranolol 10 mg intravenously
Number of subjects: 20
Study: 31637435

Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Index (SHI)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Morningness‐Eveningness Questionnaire (MEQ)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sleep Hygiene practices
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Psychological health interventions
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sleep patterns (bedtime and wake time)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sleep patterns (bedtime stress)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sleep patterns (planning/worrying in bed)
Number of subjects: 202
Study: 30952158

Group type: EXPERIMENTAL
Intervention: Chloroquine (25mg base/kg) plus primaquine (0.5 mg/kg/day for 14 days)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Chloroquine (25mg base/kg) plus primaquine (1 mg/kg/day for 7 days)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine (0.5 mg/kg/day for 14 days)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine (1 mg/kg/day for 7 days)
Number of subjects: 680

Group type: COMPARATOR
Intervention: 14-day high-dose primaquine regimen
Number of subjects: 680

Group type: COMPARATOR
Intervention: 7-day high-dose primaquine regimen
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: G6PD female heterozygotes
Number of subjects: 680
Study: 28938439

Group type: EXPERIMENTAL
Intervention: 1500 mg metformin with cholecystokinin (0.4 pmol × kg‐1 × min‐1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1500 mg metformin without cholecystokinin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo with cholecystokinin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo without cholecystokinin
Number of subjects: 15
Study: 25945045

Group type: EXPERIMENTAL
Intervention: SFC 250 (salmeterol 50 mcg and fluticasone propionate 250 mcg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SFC 250
Number of subjects: 52
Study: 22404879

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT) consisting of eight 1-hour sessions over 4 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT)
Number of subjects: 16
Study: 21701060

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 9
Study: 17442602

Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (10mg)
Number of subjects: 12
Study: 16368074

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CBT combined with hypnosis
Number of subjects: 87

Group type: COMPARATOR
Intervention: Supportive Counselling (SC)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 87
Study: 14658582

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant chemo-radiotherapy
Number of subjects: 0
Study: 11172237

Group type: EXPERIMENTAL
Intervention: Cognitive group therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiential group therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9257749

Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg intravenously twice a day for 4 days (Group B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg intravenously twice a day for 4 days and Sucralfate 2 g orally three times a day for 7 days (Group A)
Number of subjects: 16
Study: 8292694

Group type: EXPERIMENTAL
Intervention: Dexamethasone Suppression Test (DST) alone
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone (TRH) test alone
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Both DST and TRH tests
Number of subjects: 166

Group type: COMPARATOR
Intervention: No neuroendocrine tests administered
Number of subjects: 166
Study: 3802690

Group type: EXPERIMENTAL
Intervention: Controlled release oral morphine sulphate (MS-Contin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Solution of oral morphine sulphate
Number of subjects: 0
Study: 30595364

Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg/d for 6 months
Number of subjects: 36
Study: 26498427

Group type: EXPERIMENTAL
Intervention: 400 ml 0.4% CHO ingested serially via 25 ml boluses
Number of subjects: 10

Group type: COMPARATOR
Intervention: 375 ml 0% CHO control (CON) ingested followed by one 25 ml 6% CHO mouth rinse
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON ingest followed by CON rinse
Number of subjects: 10
Study: 24784756

Group type: EXPERIMENTAL
Intervention: Eyes open alpha power training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Random beta power training (control)
Number of subjects: 12
Study: 22407780

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combination of curcumin and diclofenac sodium
Number of subjects: 45
Study: 20879879

Group type: EXPERIMENTAL
Intervention: R788 100 mg twice daily
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: R788 150 mg once daily
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 19027430

Group type: EXPERIMENTAL
Intervention: Trained coders (EA and AA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Untrained coders (EA and AA)
Number of subjects: 8
Study: 15992643

Group type: COMPARATOR
Intervention: 20 mg/day simvastatin (conventional therapy)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 80 mg/day simvastatin (aggressive therapy)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups (20 mg and 80 mg simvastatin)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Patients reaching mean on-treatment LDL-C < or = 100 mg/dl
Number of subjects: 51
Study: 12574182

Group type: EXPERIMENTAL
Intervention: PTHrP (6.56 microg/kg x d, or approximately 400 microg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 16
Study: 11360608

Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Mifepristone 25 mg
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Mifepristone 10 mg
Number of subjects: 639
Study: 8722392

Group type: EXPERIMENTAL
Intervention: Omeprazole with successful eradication of H. pylori
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole with placebo (failed eradication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole with amoxycillin (failed eradication)
Number of subjects: 0
Study: 1986952

Group type: EXPERIMENTAL
Intervention: Luteal support therapy (intramuscular injections of progesterone and/or human chorionic gonadotropin)
Number of subjects: 207
Study: 3916369

Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranicotinate (Perycit) 750 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28084833

Group type: EXPERIMENTAL
Intervention: Specific balance training included in endurance‐resistance training (n=26)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Resistance‐endurance training only (n=23)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Specific balance training included in endurance‐resistance training
Number of subjects: 49
Study: 27533097

Group type: EXPERIMENTAL
Intervention: Insecticide impregnated durable wall lining (DWL)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Insecticide treated nets (ITN)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Environmental management (EM)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200
Study: 24387824

Group type: EXPERIMENTAL
Intervention: Semi-automated volumetric measurements of functional parameters (ADC, AE, VE) before and after intra-arterial therapy (IAT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Semi-automated measurements of tumor volume and size in the axial plane before and after IAT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Semi-automated measurements of change in tumor RECIST size
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EASL measurements of tumor enhancement in the axial plane before and after IAT
Number of subjects: 50
Study: 23166343

Group type: EXPERIMENTAL
Intervention: Continuous-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks over 48 hours)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bolus-infusion doxorubicin (360 mg/m2 in 30 mg/m2 doses every 3 weeks within 15 minutes)
Number of subjects: 102
Study: 20513677

Group type: EXPERIMENTAL
Intervention: Together Facing the Challenge intervention with additional training and consultation to staff and treatment foster parents
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control group receiving usual training and treatment
Number of subjects: 247
Study: 17989698

Group type: EXPERIMENTAL
Intervention: 5% albumin (ALB)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 5% albumin (ALB) and Normal saline (NS)
Number of subjects: 101
Study: 17588394

Group type: EXPERIMENTAL
Intervention: 5 mg of oral vitamin K
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Warfarin cessation 6 days preoperatively
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg until the evening before surgery
Number of subjects: 40
Study: 14996525

Group type: EXPERIMENTAL
Intervention: Olanzapine (6-20 mg/d)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: OFC (6/25, 12/25, or 12/50 mg/d)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 833
Study: 11004094

Group type: EXPERIMENTAL
Intervention: Optical measurement (Orbscan topograph system)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ultrasound measurement (standard A-scan)
Number of subjects: 18
Study: 9343462

Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 361
Study: 8450994

Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Prednisone 0.3 mg/kg/d
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Azathioprine 2 to 2.5 mg/kg/d
Number of subjects: 99
Study: 3708119

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 3)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 4)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 5)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 6)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 40 mg furosemide tablet (Product 7)
Number of subjects: 14
Study: 31536522

Group type: EXPERIMENTAL
Intervention: Inspiratory loading (INSP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MATCH exercise
Number of subjects: 10
Study: 27687681

Group type: EXPERIMENTAL
Intervention: Dose escalation, 1500 SW at 18 kV, followed by 1500 SW at 20 kV then 1500 SW at 22 kV
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Constant dose, 4500 SW at 20 kV
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dose reduction, 1500 SW at 22 kV, followed by 1500 SW at 20 kV and then 1500 SW at 18 kV
Number of subjects: 150
Study: 26117944

Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g, bid)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg, qd)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Qilin Pills plus sertraline
Number of subjects: 120
Study: 24620654

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined radiotherapy (34 patients)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Chemotherapy (23 patients)
Number of subjects: 57
Study: 21455074

Group type: EXPERIMENTAL
Intervention: Neostigmine group (neostigmine 20 μg kg‐1)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo group (saline)
Number of subjects: 132
Study: 19878605

Group type: EXPERIMENTAL
Intervention: Pedometer-based Green Prescription
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional time-based Green Prescription
Number of subjects: 100
Study: 16483622

Group type: EXPERIMENTAL
Intervention: Regimen A (3.6 mg/kg for all i.v. injections, given as three series of three injections separated by 1-week intervals)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Regimen B (10 consecutive daily i.v. injections of 2.16 mg/kg)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Regimen C (graded dosing: 1.8, 2.16, 2.52, 2.52, 2.88, 3.24, then 3.6 mg/kg for the last three injections)
Number of subjects: 389
Study: 12574768

Group type: EXPERIMENTAL
Intervention: Percutaneous tracheostomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open tracheostomy
Number of subjects: 24
Study: 10839903

Group type: EXPERIMENTAL
Intervention: 2.5 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 5.0 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 7.5 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 10.0 microg sufentanil combined with 2.5 mg bupivacaine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (0 microg sufentanil combined with 2.5 mg bupivacaine)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 10.0 microg sufentanil
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: 7.5 and 10.0 microg sufentanil
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: All groups (2.5, 5.0, 7.5, 10.0 microg sufentanil)
Number of subjects: 170
Study: 9352866

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg three times daily)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 118
Study: 8222480

Group type: EXPERIMENTAL
Intervention: 10 mg extended‐release felodipine once daily for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo once daily for 2 weeks
Number of subjects: 12
Study: 3811793

Group type: EXPERIMENTAL
Intervention: Ketogan (ketobemidone 5 mg + A-29 25 mg)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Morphine + scopolamine (10 mg + 0.4 mg)
Number of subjects: 227
Study: 31002403

Group type: EXPERIMENTAL
Intervention: Caregiver assessment documentation
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Caregiver support provision
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Self-reported relationship problems
Number of subjects: 211
Study: 29716449

Group type: EXPERIMENTAL
Intervention: Thinking Skills for Work program (enhanced supported employment plus cognitive remediation)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Enhanced supported employment only
Number of subjects: 107
Study: 27107287

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (AS-MQ)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 103
Study: 25273932

Group type: EXPERIMENTAL
Intervention: Exercise programme (low-to-moderate intensity, 3 times a week for 12 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (maintained current lifestyle)
Number of subjects: 55
Study: 22192641

Group type: EXPERIMENTAL
Intervention: LC15-0444 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coadministration of LC15-0444 and pioglitazone
Number of subjects: 0
Study: 20014133

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol supplementation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17921364

Group type: EXPERIMENTAL
Intervention: Weight velocity from 1 y and 9 mo to 5 y of age
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Infant weight gain from 5 mo to 1 y and 9 mo
Number of subjects: 679